These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Survival with intraperitoneal cisplatin in advanced ovarian cancer after second-look laparotomy. de Gramont A; Demuynck B; Louvet C; Gonzalez-Canali G; Varette C; Pigné A; Marpeau L; Herbulot P; Lagadec B; Cady J Am J Clin Oncol; 1992 Feb; 15(1):7-11. PubMed ID: 1550083 [TBL] [Abstract][Full Text] [Related]
5. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501 [TBL] [Abstract][Full Text] [Related]
6. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer. Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048 [TBL] [Abstract][Full Text] [Related]
7. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. Howell SB; Zimm S; Markman M; Abramson IS; Cleary S; Lucas WE; Weiss RJ J Clin Oncol; 1987 Oct; 5(10):1607-12. PubMed ID: 2443622 [TBL] [Abstract][Full Text] [Related]
8. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma]. Zhao XD; Zhang Q; Zhang Y Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882 [TBL] [Abstract][Full Text] [Related]
9. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer]. Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544 [TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission. Menczer J; Ben-Baruch G; Rizel S; Brenner H Gynecol Oncol; 1992 Aug; 46(2):222-5. PubMed ID: 1500025 [TBL] [Abstract][Full Text] [Related]
11. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission. Tournigand C; Louvet C; Molitor JL; Fritel X; Dehni N; Sezeur A; Pigné A; Cady J; Milliez J; de Gramont A Gynecol Oncol; 2003 Nov; 91(2):341-5. PubMed ID: 14599864 [TBL] [Abstract][Full Text] [Related]
12. Ip chemotherapy employing a regimen of cisplatin, cytarabine, and bleomycin. Markman M; Cleary S; Lucas W; Weiss R; Howell SB Cancer Treat Rep; 1986 Jun; 70(6):755-60. PubMed ID: 2425962 [TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Yen MS; Juang CM; Lai CR; Chao GC; Ng HT; Yuan CC Int J Gynaecol Obstet; 2001 Jan; 72(1):55-60. PubMed ID: 11146078 [TBL] [Abstract][Full Text] [Related]